Who
Aaron Royston
Director
Company insider
Files Form 4 as: Director, Achieve Life Sciences; Director and 10% owner, Ventyx Biosciences; 10% owner, Elevation Oncology; Director, Yarrow Bioscience; Director, Akero Therapeutics.
In numbers
- Trades disclosed
- 20
- Buys
- 3
- Sells
- 0
- Bought
- $19.0M
- Sold
- $0
- Companies
- 5
- Companies where not an officer
- 5
- First trade
- 24 Jun 2019
- Last trade
- 27 Jul 2026
- Last filed
- 29 Jul 2026
Companies traded
Activity over time
1 Nov 2024 – 1 Oct 2026
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 27 Jul 2026filed 29 Jul 2026 | ACHV Achieve Life Sciencesoption or derivative · Diagnostics & Labs | SEC FORM 4 Code A | —25,000 at $0.00 | filing |
| 27 Jul 2026filed 29 Jul 2026 | ACHV Achieve Life Sciencesoption or derivative · Diagnostics & Labs | SEC FORM 4 Code A | —16,700 at $0.00 | filing |
| 27 Jul 2026filed 29 Jul 2026 | ACHV Achieve Life Sciencesoption or derivative · Diagnostics & Labs | SEC FORM 4 Code A | —25,000 at $0.00 | filing |
| 27 Jul 2026filed 29 Jul 2026 | ACHV Achieve Life Sciencesoption or derivative · Diagnostics & Labs | SEC FORM 4 Code A | —16,700 at $0.00 | filing |
| 9 Jun 2022filed 26 Apr 2023 | Ventyx Biosciencesoption or derivative | SEC FORM 4 Code A | —21,825 at $0.00 | filing |
| 9 Jun 2022filed 10 Jun 2022 | Ventyx Biosciencesoption or derivative | SEC FORM 4 Code A | —13,301 at $0.00 | filing |
| 25 Oct 2021filed 25 Oct 2021 | Ventyx Biosciencesoption or derivative | SEC FORM 4 Code C | —3,289,742 at $0.00 | filing |
| 25 Oct 2021filed 25 Oct 2021 | Ventyx Biosciencesoption or derivative | SEC FORM 4 Code C | —395,027 at $0.00 | filing |
| 25 Oct 2021filed 25 Oct 2021 | Ventyx Biosciences | SEC FORM 4 Code C | —3,684,769 at $0.00 | filing |
| 25 Oct 2021filed 25 Oct 2021 | Ventyx Biosciences | SEC FORM 4 Bought | $5.0M312,500 at $16.00 | filing |
| 29 Jun 2021filed 1 Jul 2021 | Elevation Oncologyoption or derivative | SEC FORM 4 Code C | —8,380,034 at $0.00 | filing |
| 29 Jun 2021filed 1 Jul 2021 | Elevation Oncology | SEC FORM 4 Code C | —1,983,167 | filing |
| 29 Jun 2021filed 1 Jul 2021 | Elevation Oncology | SEC FORM 4 Bought | $10.0M625,000 at $16.00 | filing |
| 25 Jun 2019filed 8 Aug 2019 | YARW Yarrow Bioscienceoption or derivative · Biotechnology | SEC FORM 4 Code A | —22,500 at $0.00 | filing |
| 25 Jun 2019filed 27 Jun 2019 | YARW Yarrow Bioscienceoption or derivative · Biotechnology | SEC FORM 4 Code A | —22,500 at $0.00 | filing |
| 24 Jun 2019filed 25 Jun 2019 | Akero Therapeuticsoption or derivative | SEC FORM 4 Code C | —10,666,667 at $0.00 | filing |
| 24 Jun 2019filed 25 Jun 2019 | Akero Therapeuticsoption or derivative | SEC FORM 4 Code C | —722,737 at $0.00 | filing |
| 24 Jun 2019filed 25 Jun 2019 | Akero Therapeutics | SEC FORM 4 Bought | $4.0M250,000 at $16.00 | filing |
| 24 Jun 2019filed 25 Jun 2019 | Akero Therapeutics | SEC FORM 4 Code C | —3,469,759 | filing |
| 24 Jun 2019filed 25 Jun 2019 | Akero Therapeutics | SEC FORM 4 Code C | —235,099 | filing |
News
No headline names them, or the companies they trade most, lately.